My watch list

Nateglinide


Nateglinide
Systematic (IUPAC) name
3-phenyl-2-(4-propan-2-ylcyclohexyl) carbonylamino-propanoic acid
Identifiers
CAS number	105816-04-4
ATC code	A10BX03
PubChem	60026
DrugBank	APRD00593
Chemical data
Formula	C₁₉H₂₇NO₃
Mol. mass	317.423 g/mol
Pharmacokinetic data
Bioavailability	?
Protein binding	98%
Metabolism	?
Half life	1.5 hours
Excretion	?
Therapeutic considerations
Licence data	EU US
Pregnancy cat.	?
Legal status
Routes	?

Nateglinide (INN, trade name Starlix) is a drug for the treatment of type 2 diabetes. Nateglinide was developed by the Swiss pharmaceutical company Novartis.

Additional recommended knowledge

Correct Test Weight Handling Guide: 12 Practical Tips

Don't let static charges disrupt your weighing accuracy

Daily Sensitivity Test

Nateglinide belongs to the meglitinide class of blood glucose-lowering drugs.

Pharmacology

Nateglinide lowers blood glucose by stimulating the release of insulin from the pancreas. It achieves this by closing ATP-dependent potassium channels in the membrane of the β cells. This depolarizes the β cells and causes voltage-gated calcium channels to open. The resulting calcium influx induces fusion of insulin-containing vesicles with the cell membrane, and insulin secretion occurs.

Dosage

Nateglinide is delivered in 60mg & 120mg tablet form.

v • d • e Oral antidiabetic drugs and Insulin analogs (A10)
Biguanides	Metformin
Sulfonylureas	Chlorpropamide, Glibenclamide (Glyburide), Gliclazide, Glimepiride, Glipizide, Gliquidone, Tolazamide, Tolbutamide
Alpha-glucosidase inhibitors	Acarbose, Miglitol, Voglibose
Thiazolidinediones (TZD)	Pioglitazone, Rosiglitazone, Troglitazone
Meglitinides	Nateglinide, Repaglinide, Mitiglinide
Dipeptidyl peptidase-4 (DPP-4) inhibitors	Saxagliptin, Sitagliptin, Vildagliptin
Glucagon-like peptide-1 analog	Exenatide
Insulin analogs	fast acting (Insulin lispro, Insulin aspart, Insulin glulisine), intermediate-acting (NPH insulin), long acting (Insulin glargine, Insulin detemir)